Compare JZXN & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JZXN | SRTS |
|---|---|---|
| Founded | 2019 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.6M | 45.6M |
| IPO Year | 2020 | 2016 |
| Metric | JZXN | SRTS |
|---|---|---|
| Price | $0.91 | $2.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 53.9K | ★ 556.2K |
| Earning Date | 02-24-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,482,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $46.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.12 | $2.31 |
| 52 Week High | $8.50 | $5.49 |
| Indicator | JZXN | SRTS |
|---|---|---|
| Relative Strength Index (RSI) | 35.47 | 34.96 |
| Support Level | $0.89 | N/A |
| Resistance Level | $1.20 | $3.35 |
| Average True Range (ATR) | 0.07 | 0.51 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 22.29 | 1.02 |
Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It is into trade business with a focus on sales of new energy batteries including design, commissioned processing, transportation and packaging, sales of electrical equipment, mobile phone accessories and other products. Its revenues consist of two reportable operating segments: (i) Sales of new energy batteries, including production, transportation, and packaging, in the mainland Pearl River Delta region; and(ii) Sales and production of electric vehicles in Southeast Asia, including two-wheelers, three-wheeled electric scooters, and slow-speed vehicles.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.